Lab
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings was paid $899K by Medicaid between Jan 2018 and Dec 2024, across 143 billing codes. Its largest line is 80050, General health panel — 17% of everything it billed.
33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
MC KENZIE, TN 38201
MC KENZIE, TN 38201
33aNPI1760993034assigned 10/13/2017
33bProvider typeClinical Medical Laboratory
28Total paid$899K
24GClaims328,487
24DCodes billed143
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Tennessee
Rank by total paid#25 of 70
Median peer was paid$141K
This provider vs. median6.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,569 | $44K | |
| 2019 | 70,637 | $228K | |
| 2020 | 46,994 | $99K | |
| 2021 | 54,792 | $113K | |
| 2022 | 52,753 | $124K | |
| 2023 | 57,035 | $170K | |
| 2024incomplete | 28,707 | $120K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80050 | General health panel | 17% | 12,510 | 9,876 | $157K |
| 80061 | Lipid panel | 9.5% | 32,687 | 25,991 | $85K |
| 80053 | Comprehensive metabolic panel | 8.0% | 35,330 | 28,376 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.0% | 29,909 | 23,811 | $63K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 5.9% | 24,275 | 20,250 | $53K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.3% | 8,495 | 6,458 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.9% | 15,005 | 11,740 | $35K |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.9% | 21,486 | 17,154 | $35K |
| 87186 | 2.2% | 8,217 | 7,003 | $20K | |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 8,138 | 6,808 | $15K |
| 82607 | 1.7% | 5,902 | 4,428 | $15K | |
| 81025 | 1.7% | 4,142 | 2,847 | $15K |
131 more codes
| 87088 | 1.7% | 7,495 | $15K | |
| 84439 | 1.6% | 7,824 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 8,290 | $14K |
| 82728 | 1.2% | 4,727 | $11K | |
| 83880 | 1.1% | 1,451 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.1% | 570 | $10K |
| 84702 | <1% | 1,898 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 369 | $8K |
| 85027 | <1% | 5,515 | $8K | |
| 84153 | <1% | 2,603 | $8K | |
| 82746 | <1% | 2,881 | $7K | |
| 83550 | <1% | 5,005 | $7K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 765 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 758 | $7K |
| 82570 | <1% | 5,028 | $6K | |
| 87077 | <1% | 3,506 | $6K | |
| 87070 | <1% | 2,780 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 259 | $6K |
| 83540 | <1% | 5,322 | $6K | |
| 87081 | <1% | 2,220 | $5K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 521 | $5K |
| 81003 | <1% | 8,527 | $5K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,078 | $5K |
| 87807 | <1% | 829 | $5K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 30 | $5K |
| 83735 | <1% | 2,625 | $4K | |
| 85610 | <1% | 3,375 | $4K | |
| 84403 | <1% | 670 | $4K | |
| 80074 | <1% | 909 | $4K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 127 | $4K |
| 82043 | <1% | 4,270 | $4K | |
| 80055 | <1% | 309 | $4K | |
| 82247 | <1% | 1,525 | $3K | |
| 81001 | <1% | 3,174 | $3K | |
| 83690 | <1% | 984 | $2K | |
| 86140 | <1% | 2,038 | $2K | |
| 83655 | <1% | 344 | $2K | |
| 86803 | <1% | 664 | $2K | |
| 86850 | <1% | 333 | $2K | |
| 82248 | <1% | 1,043 | $2K | |
| 84481 | <1% | 574 | $2K | |
| 85652 | <1% | 1,948 | $2K | |
| 83001 | <1% | 311 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 99 | $2K |
| 82670 | <1% | 181 | $1K | |
| 87522 | Neg quan hep c or qual rna | <1% | 104 | $1K |
| 82150 | <1% | 647 | $1K | |
| 84436 | <1% | 1,144 | $1K | |
| 84550 | <1% | 1,507 | $1K | |
| 87420 | <1% | 216 | $1K | |
| 86003 | <1% | 111 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 147 | $1K |
| 83970 | <1% | 204 | $1K | |
| 87902 | <1% | 19 | $1K | |
| 83002 | <1% | 239 | $1K | |
| 86757 | <1% | 112 | $1K | |
| 84146 | <1% | 235 | $1K | |
| 84156 | <1% | 880 | $1K | |
| 84479 | <1% | 813 | $946.50 | |
| 87536 | <1% | 17 | $896.74 | |
| 88141 | <1% | 152 | $809.47 | |
| 81329 | <1% | 26 | $783.83 | |
| 86618 | <1% | 88 | $713.78 | |
| 82465 | <1% | 451 | $675.46 | |
| 83516 | <1% | 109 | $657.23 | |
| 86900 | <1% | 369 | $573.05 | |
| 86901 | <1% | 369 | $570.95 | |
| 87210 | <1% | 361 | $559.28 | |
| 84144 | <1% | 112 | $549.76 | |
| 83615 | <1% | 387 | $501.87 | |
| 86592 | <1% | 612 | $492.96 | |
| 83525 | <1% | 206 | $491.69 | |
| 86038 | <1% | 255 | $483.87 | |
| 87340 | <1% | 192 | $428.18 | |
| 86696 | <1% | 142 | $407.94 | |
| 84402 | <1% | 66 | $392.16 | |
| 84450 | <1% | 284 | $337.78 | |
| 82565 | <1% | 209 | $334.23 | |
| 82105 | <1% | 205 | $326.40 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 38 | $311.68 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 23 | $309.52 |
| 82784 | <1% | 68 | $301.20 | |
| 82677 | <1% | 65 | $294.15 | |
| 84681 | <1% | 72 | $284.43 | |
| 84480 | <1% | 127 | $248.01 | |
| 83021 | <1% | 47 | $247.62 | |
| 82627 | <1% | 34 | $236.98 | |
| 86695 | <1% | 139 | $235.18 | |
| 84460 | <1% | 225 | $210.42 | |
| 86336 | <1% | 68 | $189.45 | |
| 86200 | <1% | 91 | $176.20 | |
| 86617 | <1% | 16 | $175.84 | |
| 86431 | <1% | 210 | $173.40 | |
| 82785 | <1% | 20 | $160.20 | |
| 82950 | <1% | 114 | $153.03 | |
| 84075 | <1% | 181 | $149.71 | |
| 80076 | <1% | 89 | $136.30 | |
| 86666 | <1% | 17 | $132.00 | |
| 82040 | <1% | 189 | $126.81 | |
| 85730 | <1% | 97 | $122.34 | |
| 82140 | <1% | 21 | $117.85 | |
| 86255 | <1% | 41 | $117.24 | |
| 85018 | <1% | 202 | $114.80 | |
| 86376 | <1% | 91 | $104.48 | |
| 84484 | <1% | 26 | $103.50 | |
| 84100 | <1% | 94 | $101.73 | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 81 | $85.83 |
| 85660 | <1% | 42 | $84.60 | |
| 85045 | <1% | 147 | $66.93 | |
| 86225 | <1% | 31 | $66.78 | |
| S3600 | Stat laboratory request (situations other than s3601) | <1% | 2,209 | $56.58 |
| 85014 | <1% | 152 | $54.78 | |
| 82378 | <1% | 15 | $52.76 | |
| 84132 | <1% | 38 | $44.22 | |
| 86704 | <1% | 16 | $39.08 | |
| 82550 | <1% | 32 | $31.54 | |
| 87075 | <1% | 13 | $31.02 | |
| 86706 | <1% | 34 | $29.85 | |
| 85379 | <1% | 20 | $29.72 | |
| 82947 | <1% | 13 | $25.52 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 12 | $24.62 |
| 82977 | <1% | 34 | $20.00 | |
| 80069 | <1% | 16 | $11.20 | |
| 85041 | <1% | 27 | $7.29 | |
| 85048 | <1% | 27 | $6.15 | |
| 80164 | <1% | 15 | $5.78 | |
| 86800 | <1% | 36 | $5.56 | |
| 36416 | <1% | 65 | $0.15 | |
| 80177 | 0% | 15 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 137 | $0.00 |
| 86235 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.